Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent
A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry
Sponsor: Johnson and Johnson, S.A.
This observational or N/A phase trial investigates Coronary Arteriosclerosis and is currently completed. Johnson and Johnson, S.A. leads this study, which shows 10 recorded versions since 2009 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 5 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson and Johnson, S.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albacete, Spain , Almada, Portugal , Badalona, Spain , Barcelona, Spain , L'Hospitalet de Llobregat, Spain , Lisbon, Portugal , Lleida, Spain , Oviedo, Spain , Porto, Portugal , Sant Cugat del Vallès, Spain and 2 more locations